EASD 2017 research news: Diabetic complications

An EASD session on optimizing patient outcomes included research into the effect of guideline adherence, predictors of changes in medication adherence, and overtreatment of older people with diabetes.

Results of a pooled analysis suggest that the 300 U/mL dose of insulin glargine is associated with a lower risk for hypoglycemia than the 100 U/mL dose.

Results presented during an EASD annual meeting session on hypoglycemia covered risk factors and consequences, and looked at the optimal insulin management approach for diabetes patients wishing to observe Ramadan.

Researchers presented the results of several studies investigating the risks associated with nonalcoholic fatty liver disease and potential treatment strategies at the EASD annual meeting in Lisbon, Portugal.

Sotagliflozin may be an effective add-on therapy to insulin for patients with type 1 diabetes, but the benefits are less clear in a young adult population, suggest the results of two studies presented at the EASD annual meeting in Lisbon, Portugal.

Researchers find that routinely asking patients with type 1 diabetes to complete the Diabetes Distress Scale-2 may direct more healthcare resources to those who need them and help to improve outcomes.

Asking two simple questions about the vitality and energy of patients with type 2 diabetes may help healthcare providers to predict their risk for major adverse cardiovascular events.

The J-DIOT3 trial results support the findings from Steno-2, showing that intensive risk factor management can reduce the risk for complications in patients with type 2 diabetes.

Two secondary analyses of the DEVOTE trial suggest that type 2 diabetes patients with high day-to-day fasting glycemic variability and those who experience severe hypoglycemia are at increased risk for adverse outcomes.

Physical activity is linked to lower mortality risk among patients with type 1 diabetes irrespective of whether they have comorbid chronic kidney disease, study results suggest.

Dapagliflozin is a promising adjunct treatment to insulin for patients with type 1 diabetes, suggest phase III trial results presented at the EASD annual meeting in Lisbon, Portugal, and published simultaneously in The Lancet Diabetes & Endocrinology.

Results from Steno-2 show that intensive multifactorial treatment reduces the risk for heart failure in patients with type 2 diabetes and microalbuminuria.

Results of the inTandem3 study suggest that adding the sodium–glucose cotransporter 1 and 2 inhibitor sotagliflozin to insulin treatment improves glycemic control among patients with type 1 diabetes, but at the cost of an increased risk for ketoacidosis.

Results of a randomized trial suggest that patients with type 2 diabetes experience metabolic benefits from a hypocaloric diet regardless of whether it is low in fat or low in carbohydrate content.

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.